Loading clinical trials...
Loading clinical trials...
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
CTI BioPharma
NCT07357727 · Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (PPV-MF), and more
NCT06976918 · Primary Myelofibrosis, Secondary Myelofibrosis, and more
NCT06343805 · Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, and more
NCT06327100 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, and more
NCT06361641 · Myeloproliferative Neoplasm, Polycythemia Vera, and more
CTI Investigational Site 10002
Scottsdale, Arizona
CTI Investigational Site 10004
Omaha, Nebraska
CTI Investigational Site 10001
Morristown, New Jersey
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions